PnuBioVax™: next-generation vaccine for a personalised and effective immune response against Streptococcus pneumoniae.

Informacje na temat projektu

PnuBioVax

Identyfikator umowy o grant: 866570

DOI

10.3030/866570

Projekt został zamknięty

Data podpisania przez KE 11 Maja 2019

Data rozpoczęcia 1 Maja 2019

Data zakończenia 30 Września 2019

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

IMMUNOBIOLOGY LIMITED
United Kingdom

Periodic Reporting for period 1 - PnuBioVax (PnuBioVax™: next-generation vaccine for a personalised and effective immune response against Streptococcus pneumoniae.)

Okres sprawozdawczy: 2019-05-01 do 2019-09-30

Podsumowanie kontekstu i ogólnych celów projektu

The prevention of pneumococcal diseases is a global challenge that has been partially addressed through vaccination. Some of the societal issues associated with pneumococcal diseases are that (1) they are a major cause of mortality in the young and elderly, (2) current vaccines have limited efficacy and coverage, (3) vaccination is not always accessible and (4) pneumococcal disease presents an ecoomic burden. ImmBio is developing next-generation vaccines against serious infectious disease targets, starting with a vaccine against pneumococcal disease, utilising its proprietary technology platforms to directly induce immunity via dendritic cells.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

During the Feasibility Study, ImmBio has completed a full analysis of the technical and business potential of its new vaccine. During the project the company has expanded its knowledge primarily with regards to the required clinical validation and regulatory approval for European market launch.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

PnuBioVax™ (PBV) is a next-generation, multi-antigen, serotype-independent and adjuvant-free prophylactic vaccine against invasive pneumococcal disease. Although most competing vaccines are effective against the variants they specifically target, there are significant issues associated with them; i) high production costs, ii) low breadth of protection, iii) promotion of antibiotic resistance and, iv) their efficacy depends on the prevalence of the targeted variants in the different geographical regions. Immbio intends to bring to market a clinically validated vaccine against pneumococcal disease that will increase prevention and be more widely accessible thanks to its lower cost of production.

ImmBio